Although the angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) pathway, VEGF inhibitors such as bevacizumab, sunitinib, and sorafenib, are more commonly associated with AAD owing to vasoconstriction and endothelial dysfunction,3 fluoropyrimidines have also been implicated in noncoronary vascular events, including AAD, in addition to their known cardiotoxic effects. Here, VEGFA is linked to endothelial dysfunction.